Acceleron Pharma Inc. buy tamam
Summary
This prediction ended on 05.11.21 with a price of €150.00. With a performance of 254.54% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Acceleron Pharma Inc. | - | - | - | - |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by tamam for this prediction
In the thread Acceleron Pharma Inc. diskutieren
Acceleron's Unique Pipeline looks undervalued
tamam stimmt am 04.03.2018 der fundamentalen Bewertung mit dem Ergebnis unterbewertet zu.
Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to promote red blood cell production; dalantercept, for the treatment of patients with renal cell carcinoma; and ACE-083, designed for the treatment of focal muscle disorders.
Lots of analyst commentary around Acceleron Pharma (XLRN) yesterday. Piper Jaffray ($53 price target from $40 previously), H.C. Wainwright ($62 price target) and Barclays ($54 price target) reiterated
Buy ratings on the stock Wednesday. Oppenheimer takes the other side of that bet, and assigns a Hold to XLRN.
In the thread Trading Acceleron Pharma Inc.
Stopped prediction by tamam for Acceleron Pharma Inc.
Acceleron Pharma Inc.
04.03.18
04.03.19
04.03.19
